Takeda stock: FY2026 outlook rises as pipeline advances
Published on 10/31/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTakeda enters a pivotal pipeline week
- Takeda upgraded its FY2026 outlook after reporting first-half results and continued progress in new medicines.
- Arcotatug tavatecan delivered positive Phase 3 results, supporting a planned regulatory filing in Japan.
- Takeda will present its longer-term strategy at a Capital Markets Day in December.
Takeda stock traded at 18.50 euros on Lang & Schwarz at 10:18 Berlin time on Saturday, October 31, 2026; the real-time quote of Takeda stock is available for investors. The week was shaped by Takeda's FY2026 first-half results and a positive late-stage oncology update.
First-half results lift full-year outlook
On October 29, Takeda reported first-half fiscal 2026 results for the period from April 1 through September 30. According to Takeda, revenue rose 8.4 percent on an actual exchange-rate basis to 2,407.0 billion yen, while core operating profit increased 11.2 percent to 710.6 billion yen. At constant exchange rates, revenue declined 1.0 percent and core operating profit increased 0.7 percent.
Takeda raised its FY2026 reported revenue forecast to 4,700.0 billion yen from 4,640.0 billion yen. The company also lifted its operating-profit forecast to 453.0 billion yen from 420.0 billion yen and its net-profit forecast to 209.0 billion yen from 166.0 billion yen. Management attributed the revisions mainly to a foreign-exchange benefit. The revised full-year EPS forecast is 131 yen, compared with 104 yen previously.
Oncology milestone supports Japan filing
On October 23, Takeda announced positive Phase 3 results for arcotatug tavatecan, also known as TAK-921, in previously treated CLDN18.2-positive advanced gastric or gastroesophageal junction cancer. The company announcement said the study met its dual primary endpoints of overall survival and progression-free survival.
Median overall survival was 10.2 months with the investigational treatment versus 6.9 months with treatment of physician's choice. Median progression-free survival was 7.1 months versus 3.1 months. Takeda said the findings support a planned regulatory filing in Japan and continued global development, but the compound remains investigational.
Strategy update follows in December
Takeda will host a Capital Markets Day in Tokyo on December 11, 2026. The event is scheduled to provide further detail on the company's growth strategy after new-product launches, regulatory progress and pipeline developments.
U.S. equities provide the broader market setting through the S&P 500.
